Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000627 · ClinicalTrials.gov registry record · NA
Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome
A NA study of HIV Infections and Histoplasmosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT00000627 is a NA study of HIV Infections and Histoplasmosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00000627, a NA study of HIV Infections and Histoplasmosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
Conditions Studied
Interventions
- DRUG Fluconazole
Study Locations (20)
New York
- Beth Israel Med Ctr - New York
- Cornell Univ Med Ctr - New York
- Saint Luke's - Roosevelt Hosp Ctr - New York
- Mount Sinai Med Ctr - New York
- Montefiore Drug Treatment Ctr / Bronx Municipal Hosp - The Bronx
- Montefiore Family Health Ctr / Bronx Municipal Hosp - The Bronx
- Samaritan Village Inc / Bronx Municipal Hosp - The Bronx
- Montefiore Med Ctr / Bronx Municipal Hosp - The Bronx
- North Central Bronx Hosp / Bronx Municipal Hosp - The Bronx
Missouri
- Univ of Missouri at Kansas City School of Medicine - Kansas City
- Infectious Diseases Association / Research Med Ctr - Kansas City
- St Louis Regional Hosp / St Louis Regional Med Ctr - St Louis
California
- Univ of Southern California / LA County USC Med Ctr - Los Angeles
- San Francisco Veterans Administration Med Ctr - San Francisco
Indiana
- Indiana Univ Hosp - Indianapolis
- Methodist Hosp of Indiana / Life Care Clinic - Indianapolis
Massachusetts
- Baystate Med Ctr of Springfield - Springfield
- Worcester Memorial Hosp / Med Ctr of Cntrl MA-Memorial - Worcester
Alabama
- Univ of Alabama at Birmingham - Birmingham
Ohio
- Ohio State Univ Hosp Clinic - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Est. Completion | 1994-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000627
The ClinicalTrials.gov registry entry for NCT00000627 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Fluconazole is the first listed.
NCT00000627 reports 20 study locations spanning 7 distinct geographic areas - top geographies include New York, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT00000627 about?
NCT00000627 is a clinical study titled "Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome". To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the t...
What is the current status of trial NCT00000627?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. Estimated completion is 1994-11.
What conditions does trial NCT00000627 study?
This clinical trial studies the following conditions: HIV Infections, Histoplasmosis.
What interventions are being tested in trial NCT00000627?
The interventions under investigation include: Fluconazole (DRUG).
Who is sponsoring clinical trial NCT00000627?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000627 being conducted?
This trial has 20 study locations across Alabama, California, Indiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.